Compare ORKA & VIPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORKA | VIPS |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.1B |
| IPO Year | 1997 | 2012 |
| Metric | ORKA | VIPS |
|---|---|---|
| Price | $79.92 | $12.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $155.00 | $16.29 |
| AVG Volume (30 Days) | 985.1K | ★ 2.4M |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | ★ 4.81% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.87 |
| P/E Ratio | ★ N/A | $9.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.88 | $12.02 |
| 52 Week High | $115.52 | $20.49 |
| Indicator | ORKA | VIPS |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 52.07 |
| Support Level | $54.31 | $12.75 |
| Resistance Level | $97.45 | $14.93 |
| Average True Range (ATR) | 4.22 | 0.24 |
| MACD | -0.39 | 0.12 |
| Stochastic Oscillator | 20.72 | 72.13 |
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.